Onesource Specialty Pharma quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	516	376	+37.4%
EBITDA	163	106	+53.3%
EBITDA margin	31.6%	28.3%	+3.3 pts
Profit before tax	52.9	5.7	+820.8%
Net profit	57.5	10.5	+448.2%
EPS	₹5.01	₹0.92	+444.6%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024

Expenses
	516	449	428	290	376	327	426	393	68.0
	1.0	3.8	2.1	4.6	3.0	5.3	2.9	5.4	0.6
	517	453	430	295	379	333	429	398	68.6
	152	141	145	87.7	124	83.4	91.0	92.9	12.3
	0.0	0.0	0.0	0.0	0.0	0.0	−8.0	0.0	0.0
	−4.8	1.1	1.8	6.6	−10.1	9.6	27.9	8.7	0.0
	77.6	68.7	62.7	64.2	62.8	58.4	51.1	57.3	22.8
	34.6	30.8	22.5	38.2	34.0	27.5	33.4	45.8	20.7
	75.1	71.7	71.8	69.6	69.8	67.8	68.5	68.8	19.1
	128	115	127	114	93.0	87.4	81.5	90.5	32.8
	463	428	431	381	373	334	345	364	108
	163	123	91.9	17.3	106	88.5	183	143	0.1
	88.2	51.6	20.1	−52.3	36.7	20.7	114	74.4	−18.9
Profit
	54.6	24.6	−0.3	−85.9	5.7	−1.5	83.5	34.0	−39.1
	−1.8	−4.3	0.0	−7.1	0.0	−2.9	0.0	−101	0.0
	52.9	20.3	−0.3	−93.0	5.7	−4.4	83.5	−66.5	−39.1
	0.3	0.3	0.5	0.6	0.9	0.2	−10.7	6.0	0.0
	−4.9	−5.0	−5.4	−5.0	−5.6	−4.4	−4.7	−3.6	0.0
	−4.6	−4.7	−4.9	−4.3	−4.7	−4.2	−15.4	2.3	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.2
	57.5	25.0	4.6	−88.7	10.5	−0.2	98.2	−68.8	−39.3
	57.5	25.0	4.6	−88.7	10.5	−0.2	98.9	−68.8	−39.1
	0.0	0.0	0.0	0.0	0.0	0.0	−0.7	0.0	0.0
	3.2	3.6	10.7	−3.4	5.8	3.0	2.2	0.0	0.0
	60.6	28.6	15.3	−92.1	16.3	2.8	100	−68.8	−39.3
	—	—	4.6	−88.7	—	—	—	—	—
	0.0	0.0	0.0	0.0	—	—	—	−1.9	0.0
Per share
	₹5.01	₹2.18	₹0.40	−₹7.74	₹0.92	−₹0.02	₹8.61	−₹6.31	−₹18.82
	₹5.01	₹2.18	₹0.40	−₹7.74	₹0.91	−₹0.02	₹8.59	−₹6.31	−₹18.82
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	0.0	0.0	−0.7	0.0	0.0
Other comprehensive income — detail
	3.2	3.6	10.7	−3.4	5.8	3.0	2.2	—	—
	0.0	1.2	−1.1	−5.5	5.8	3.0	—	—	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	−2.2	—	—
	3.1	2.4	11.8	2.1	—	—	—	—	—
	—	—	15.3	−92.1	—	—	—	—	—
Per share — as-filed variants
	₹5.01	₹2.18	₹0.40	−₹7.74	₹0.92	−₹0.02	₹8.61	−₹6.31	−₹9.41
	₹5.01	₹2.18	₹0.40	−₹7.74	₹0.91	−₹0.02	₹8.59	−₹6.31	−₹9.41
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	−₹9.41
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	−₹9.41
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	369	307	282	196	262	234	315	291	55.7
	71.4%	68.3%	65.8%	67.5%	69.8%	71.6%	74.0%	74.1%	81.9%
Adjusted (ex-exceptional items) — derived
	54.6	24.6	−0.3	−85.9	5.7	−1.5	83.5	34.0	−39.1
	−1.8	−4.3	0.0	−7.1	0.0	−2.9	0.0	−101	0.0
	59.3	29.3	4.6	−81.9	10.5	1.0	98.2	31.7	−39.3
	₹5.16	₹2.56	₹0.40	−₹7.15	₹0.92	₹0.10	₹8.61	₹2.90	−₹18.82

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ONESOURCE₹1,569.60

Onesource Specialty Pharma Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSTAR DIVISLAB GLAND PFIZER POLYMED RAINBOW KIMS JUBLPHARMAMcap ₹17,991 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	68.0	392.6	426.0	327.3	375.8	290.3	428.2	449.0	516.2
Other Income	0.6	5.4	2.9	5.3	3.0	4.6	2.1	3.8	1.0
Total Income	68.6	398.0	428.8	332.5	378.8	295.0	430.3	452.8	517.2
Expenses
+ Cost of Materials Consumed	12.3	92.9	91.0	83.4	123.5	87.7	144.5	141.2	152.3
+ Purchases of Stock-in-Trade	0.0	0.0	-8.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Changes in Inventories	0.0	8.7	27.9	9.6	-10.1	6.6	1.8	1.1	-4.8
+ Employee Benefit Expense	22.8	57.3	51.1	58.4	62.8	64.2	62.7	68.7	77.6
+ Finance Costs	20.7	45.8	33.4	27.5	34.0	38.2	22.5	30.8	34.6
+ Depreciation & Amortisation	19.1	68.8	68.5	67.8	69.8	69.6	71.8	71.7	75.1
+ Other Expenses	32.8	90.5	81.5	87.4	93.0	114.5	127.3	114.7	127.9
Total Expenses	107.6	363.9	345.3	334.1	373.1	380.9	430.6	428.2	462.6
EBITDA	0.1	143.2	182.5	88.5	106.5	17.3	91.9	123.3	163.3
EBIT	-18.9	74.4	114.0	20.7	36.7	-52.3	20.1	51.6	88.2
Profit
PBT before Exceptional Items	-39.1	34.0	83.5	-1.5	5.7	-85.9	-0.3	24.6	54.6
+ Exceptional Items	0.0	-100.5	0.0	-2.9	0.0	-7.1	0.0	-4.3	-1.8
Pretax Income	-39.1	-66.5	83.5	-4.4	5.7	-93.0	-0.3	20.3	52.9
+ Current Tax	0.0	6.0	-10.7	0.2	0.9	0.6	0.5	0.3	0.3
+ Deferred Tax	0.0	-3.6	-4.7	-4.4	-5.6	-5.0	-5.4	-5.0	-4.9
Tax Expense	0.0	2.3	-15.4	-4.2	-4.7	-4.3	-4.9	-4.7	-4.6
+ Share of Associates & JVs	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Income	-39.3	-68.8	98.2	-0.2	10.5	-88.7	4.6	25.0	57.5
+ Net Income — Continuing Ops	-39.1	-68.8	98.9	-0.2	10.5	-88.7	4.6	25.0	57.5
+ Net Income — Discontinued Ops	0.0	0.0	-0.7	0.0	0.0	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	0.0	0.0	2.2	3.0	5.8	-3.4	10.7	3.6	3.2
Total Comprehensive Income	-39.3	-68.8	100.4	2.8	16.3	-92.1	15.3	28.6	60.6
Net Income to Common	—	—	—	—	—	-88.7	4.6	—	—
Minority Interest	0.0	-1.9	—	—	—	0.0	0.0	0.0	0.0
Per Share
Basic EPS	-18.82	-6.31	8.61	-0.02	0.92	-7.74	0.40	2.18	5.01
Diluted EPS	-18.82	-6.31	8.59	-0.02	0.91	-7.74	0.40	2.18	5.01
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	0.0	-0.7	0.0	0.0	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	2.2	3.0	5.8	-3.4	10.7	3.6	3.2
+ Items NOT to be Reclassified to P&L	0.0	—	—	3.0	5.8	-5.5	-1.1	1.2	0.0
+ Tax on Items NOT to be Reclassified	—	—	-2.2	0.0	0.0	0.0	0.0	0.0	0.0
+ Items to be Reclassified to P&L	—	—	—	—	—	2.1	11.8	2.4	3.1
Comprehensive Income — Owners of Parent	—	—	—	—	—	-92.1	15.3	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	-9.41	-6.31	8.61	-0.02	0.92	-7.74	0.40	2.18	5.01
Diluted EPS — Continuing Operations	-9.41	-6.31	8.59	-0.02	0.91	-7.74	0.40	2.18	5.01
Basic EPS — Discontinued Operations	-9.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	-9.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	55.7	291.0	315.0	234.4	262.3	196.0	282.0	306.7	368.8
Gross Margin %	81.89	74.14	73.96	71.61	69.80	67.50	65.84	68.30	71.44
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-39.1	34.0	83.5	-1.5	5.7	-85.9	-0.3	24.6	54.6
− Exceptional Items (reconciliation)	0.0	-100.5	0.0	-2.9	0.0	-7.1	0.0	-4.3	-1.8
Net Income Adj (tax-effected)	-39.3	31.7	98.2	1.0	10.5	-81.9	4.6	29.3	59.3
EPS Adj	-18.82	2.90	8.61	0.10	0.92	-7.15	0.40	2.56	5.16
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Filed Debt Equity	2.00	0.00	0.16	0.19	—	—	—	—	—
Filed Dscr	0.00	0.00	2.21	—	—	—	—	—	—
Filed Iscr	-1.00	2.00	4.23	—	—	—	—	—	—
Paid Up Equity Capital	4.2	11.4	11.4	11.4	11.5	11.5	11.5	11.5	11.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Onesource Specialty Pharma Q2 FY27 results (July–September 2026)

Filed with NSE on Tuesday, 27 October 2026 at 10:07 am IST

Onesource Specialty Pharma (NSE: ONESOURCE) reported its Q2 FY27 results (July–September 2026) on Tuesday, 27 October 2026 at 10:07 am IST. Consolidated net profit was ₹57.5 crore, up 448.2% from ₹10.5 crore in Q2 FY26 and up 130.0% from ₹25 crore in Q1 FY27. Revenue from operations was ₹516 crore, up 37.4% year on year and up 15.0% from the previous quarter.

Q2 FY26 results (a year earlier): 11 November 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit: ₹57.5 Cr+448.2% vs Q2 FY26+130.0% vs Q1 FY27
Revenue from operations: ₹516 Cr+37.4% vs Q2 FY26+15.0% vs Q1 FY27
Operating margin (EBIT): 17.1%+7.3 pts vs Q2 FY26+5.6 pts vs Q1 FY27EBIT ₹88.2 Cr
EBITDA: ₹163 Cr+53.3% vs Q2 FY26+32.4% vs Q1 FY27margin 31.6%
Earnings per share (basic): ₹5.01+444.6% vs Q2 FY26+129.8% vs Q1 FY27
Net profit margin: 11.1%+8.3 pts vs Q2 FY26+5.6 pts vs Q1 FY27

Questions

What was Onesource Specialty Pharma's net profit in Q2 FY27?

Consolidated net profit was ₹57.5 crore, up 448.2% from ₹10.5 crore in Q2 FY26 and up 130.0% from ₹25 crore in Q1 FY27.

What was Onesource Specialty Pharma's revenue in Q2 FY27?

Revenue from operations was ₹516 crore, up 37.4% year on year and up 15.0% from the previous quarter.

What was Onesource Specialty Pharma's net profit in FY26?

Consolidated net profit was a loss of ₹73.8 crore in FY26 (April 2025–March 2026), wider than the loss of ₹18 crore in FY25.

How were Onesource Specialty Pharma's Q2 FY27 results?

Both grew from a year earlier: net profit was up 448.2% at ₹57.5 crore and revenue was up 37.4% at ₹516 crore. The operating margin was 17.1%, up 7.3 percentage points from 9.8% a year earlier. Against Q1 FY27, net profit was up 130.0% and revenue up 15.0%.

What was Onesource Specialty Pharma's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹88.2 crore, a margin of 17.1%, against 11.5% in Q1 FY27 and 9.8% in Q2 FY26. EBITDA was ₹163 crore, 31.6% of revenue.

What was Onesource Specialty Pharma's net profit in the first half of FY27?

Consolidated net profit for the first half of FY27 (April–September 2026) was ₹82.5 crore, up 700.9% from ₹10.3 crore in the same months a year earlier. Revenue from operations was ₹965 crore, up 37.3%.

What was Onesource Specialty Pharma's EPS in Q2 FY27?

Basic earnings per share were ₹5.01, against ₹0.92 in Q2 FY26.

What was Onesource Specialty Pharma's revenue in FY26?

Revenue from operations was ₹1,422 crore in FY26 (April 2025–March 2026), down 1.6% from ₹1,445 crore in FY25.

When did Onesource Specialty Pharma announce its Q2 FY27 results?

On Tuesday, 27 October 2026 at 10:07 am IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 11 November 2025.

What is Onesource Specialty Pharma's net profit margin?

Onesource Specialty Pharma's net profit margin was 11.1% in Q2 FY27 (net profit as a share of revenue from operations), against 2.8% in Q2 FY26 (up 8.3 percentage points). For FY26 as a whole it was −5.2%.

How has Onesource Specialty Pharma's profit changed over the last four quarters?

Net profit by quarter: a loss of ₹88.7 crore in Q3 FY26, a profit of ₹4.6 crore in Q4 FY26, a profit of ₹25 crore in Q1 FY27 and a profit of ₹57.5 crore in Q2 FY27. That is a combined loss of ₹1.6 crore over the four quarters. Revenue from operations: ₹290 crore, ₹428 crore, ₹449 crore and ₹516 crore.

When will Onesource Specialty Pharma announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Onesource Specialty Pharma figures come from?

From Onesource Specialty Pharma's own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 27 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.